Quality Systems for Regenerative Medicine Delivery; Basic Quality Requirements for Distribution - World Pharma Today

August 20, 2018

The emergence of regenerative medicine as a viable therapy class has created an urgency to review and improve upon the current quality systems distribution standards that are employed in support of these therapies. In a recent World Pharma Today featured article, Mark W. Sawicki, Ph.D., Chief Commercial officer of Cryoport, discusses the emerging Chain of Compliance® requirements for regenerative medicine distribution. Read more >

Questions or comments? We welcome your feedback!

Email Us

Tags: Clinical Trials Logistics, Temperature Controlled Logistics, Chain of Compliance®

Cryoport® is a trademark of Cryoport, Inc. and used with permission by Cryoport Systems, LLC